Manuel Haas

758 total citations
8 papers, 365 citations indexed

About

Manuel Haas is a scholar working on Molecular Biology, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Manuel Haas has authored 8 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 2 papers in Pharmacology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Manuel Haas's work include Health Systems, Economic Evaluations, Quality of Life (2 papers), Muscle Physiology and Disorders (2 papers) and Pharmaceutical Economics and Policy (2 papers). Manuel Haas is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (2 papers), Muscle Physiology and Disorders (2 papers) and Pharmaceutical Economics and Policy (2 papers). Manuel Haas collaborates with scholars based in Germany, Netherlands and Sweden. Manuel Haas's co-authors include Tomas Salmonson, Pavel Balabanov, Violeta Stoyanova‐Beninska, Bruno Sepodes, Volker Straub, Eugenio Mercuri, Annemieke Aartsma‐Rus, Francesco Muntoni, Elizabeth Vroom and Robert Hemmings and has published in prestigious journals such as Nature Reviews Drug Discovery, Multiple Sclerosis Journal and Sleep Medicine.

In The Last Decade

Manuel Haas

8 papers receiving 352 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manuel Haas Germany 7 255 62 56 40 38 8 365
Chunhong Qin China 12 205 0.8× 25 0.4× 23 0.4× 127 3.2× 30 0.8× 19 459
Atsushi Kuga Japan 9 336 1.3× 21 0.3× 46 0.8× 13 0.3× 63 1.7× 18 492
Yuta Kajiyama Japan 10 105 0.4× 13 0.2× 27 0.5× 72 1.8× 20 0.5× 29 358
Magalie P. Tardy France 6 122 0.5× 39 0.6× 28 0.5× 29 0.7× 7 0.2× 15 245
Małgorzata Dorobek Poland 9 303 1.2× 46 0.7× 35 0.6× 21 0.5× 17 0.4× 34 465
Charalampia Koutsioumpa United States 5 121 0.5× 13 0.2× 67 1.2× 17 0.4× 33 0.9× 8 255
Melanie Ullrich Germany 7 96 0.4× 28 0.5× 43 0.8× 36 0.9× 23 0.6× 17 252
Dunhui Li China 11 223 0.9× 11 0.2× 28 0.5× 26 0.7× 48 1.3× 25 441
Thomas Lapointe Canada 5 318 1.2× 13 0.2× 28 0.5× 21 0.5× 32 0.8× 16 428
Barbara Munz Germany 14 320 1.3× 53 0.9× 22 0.4× 7 0.2× 51 1.3× 36 608

Countries citing papers authored by Manuel Haas

Since Specialization
Citations

This map shows the geographic impact of Manuel Haas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Haas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Haas more than expected).

Fields of papers citing papers by Manuel Haas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Haas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Haas. The network helps show where Manuel Haas may publish in the future.

Co-authorship network of co-authors of Manuel Haas

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Haas. A scholar is included among the top collaborators of Manuel Haas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Haas. Manuel Haas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
2.
Aartsma‐Rus, Annemieke, Volker Straub, Robert Hemmings, et al.. (2017). Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues. Nucleic Acid Therapeutics. 27(5). 251–259. 125 indexed citations
3.
Butlen‐Ducuing, Florence, Frank Pétavy, Lorenzo Guizzaro, et al.. (2016). Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective. Nature Reviews Drug Discovery. 15(12). 813–814. 34 indexed citations
4.
Haas, Manuel, Valentina Mantua, Marion Haberkamp, et al.. (2015). The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. Nature Reviews Drug Discovery. 14(4). 221–222. 9 indexed citations
5.
6.
Butlen‐Ducuing, Florence, Małgorzata Zienowicz, Frank Pétavy, et al.. (2014). European regulatory experience with drugs for central nervous system disorders. Nature Reviews Drug Discovery. 14(2). 89–90. 2 indexed citations
7.
Balabanov, Pavel, Manuel Haas, André Elferink, Serge Bakchine, & Karl Broich. (2014). Addressing the regulatory and scientific challenges in multiple sclerosis – a statement from the EU regulators. Multiple Sclerosis Journal. 20(10). 1282–1287. 7 indexed citations
8.
Butlen‐Ducuing, Florence, Manuel Haas, Luca Pani, Barbara van Zwieten‐Boot, & Karl Broich. (2012). DSM-5 and clinical trials in psychiatry: challenges to come?. Nature Reviews Drug Discovery. 11(8). 583–584. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chunhong Qin Breakdown of academic impact, for papers by Atsushi Kuga Breakdown of academic impact, for papers by Yuta Kajiyama Breakdown of academic impact, for papers by Magalie P. Tardy Breakdown of academic impact, for papers by Małgorzata Dorobek Breakdown of academic impact, for papers by Charalampia Koutsioumpa Breakdown of academic impact, for papers by Melanie Ullrich Breakdown of academic impact, for papers by Dunhui Li Breakdown of academic impact, for papers by Thomas Lapointe Breakdown of academic impact, for papers by Barbara Munz
Rankless by CCL
2026